Vectus Biosystems Limited (VBS) is a public company based at Julius Avenue, North Ryde, Sydney, Australia.
Vectus has developed potentially novel treatments for fibrosis and high blood pressure which include treatment for three of the largest diseases in the fibrotic franchise, namely heart, kidney and liver disease.